Adding narrow band UVB to ruxolitinib cream after 12 weeks accelerated total body and facial repigmentation through 48 weeks ...

Please provide your email address to receive an email when new articles are posted on . More than 72% of patients were either somewhat or very satisfied with their treatment outcomes. Over 84% of ...

China Medical System Holdings ( ($HK:0867) ) just unveiled an update. China Medical System Holdings announced that its subsidiary, Dermavon ...

Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase 3 clinical trials for ...

EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Gearing Up for Phase 2 Vitiligo Trial in Mid-2026 Edesa Biotech, Inc.

Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease ...

The MarketWatch News Department was not involved in the creation of this content. HORSHAM, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ: SSKN) ...

Please provide your email address to receive an email when new articles are posted on . At week 24, the ritlecitinib plus nbUVB group saw a higher facial vitiligo severity change from baseline vs. the ...

Incyte is strutting its stuff to boost awareness and support for people with vitiligo—with help from supermodel Winnie Harlow. Harlow is the face of a newly launched campaign from Incyte—the maker of ...

The "United States Vitiligo Market Report by Diseases Type, Treatment Type, End User, Regions and Company Analysis, 2025-2033" report has been added to ResearchAndMarkets.com's offering. United States ...

‘Astonishing’ findings in mice suggest microbial product could restore skin pigmentation Offers hope for a disease that affects all skin tones, but is more visible and severe in darker skin Vitiligo ...